UA73968C2 - Glyburide in powdered form, tablets and capsules incorporating powdered glyburide, and metod for treating diabetes type ii - Google Patents

Glyburide in powdered form, tablets and capsules incorporating powdered glyburide, and metod for treating diabetes type ii Download PDF

Info

Publication number: UA73968C2
Authority: UA; Ukraine
Prior art keywords: glyburide; tablets; powdered; metod; capsules
Prior art date: 2000-01-14

Application number

UA2002086718A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-01-14

Filing date

2001-04-01

Publication date

2005-10-17

2001-04-01 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2005-10-17 Publication of UA73968C2 publication Critical patent/UA73968C2/uk

Links

229960004580 glibenclamide Drugs 0.000 title abstract description 57
ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 title abstract description 57
239000002775 capsule Substances 0.000 title abstract description 8
206010012601 diabetes mellitus Diseases 0.000 title description 2
-1 cyclohexylamino Chemical group 0.000 abstract description 5
239000002552 dosage form Substances 0.000 abstract description 5
239000008186 active pharmaceutical agent Substances 0.000 abstract 1
229940088679 drug related substance Drugs 0.000 abstract 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
239000000203 mixture Substances 0.000 description 15
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
239000002245 particle Substances 0.000 description 12
238000002360 preparation method Methods 0.000 description 12
239000000546 pharmaceutical excipient Substances 0.000 description 11
239000012907 medicinal substance Substances 0.000 description 10
229940079593 drug Drugs 0.000 description 8
239000003814 drug Substances 0.000 description 8
229920002785 Croscarmellose sodium Polymers 0.000 description 7
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 7
229960001681 croscarmellose sodium Drugs 0.000 description 7
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 7
238000000034 method Methods 0.000 description 7
239000000126 substance Substances 0.000 description 7
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 6
YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 6
238000010521 absorption reaction Methods 0.000 description 6
235000019359 magnesium stearate Nutrition 0.000 description 6
229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
229940069328 povidone Drugs 0.000 description 6
229920000168 Microcrystalline cellulose Polymers 0.000 description 5
239000004615 ingredient Substances 0.000 description 5
239000000463 material Substances 0.000 description 5
229940016286 microcrystalline cellulose Drugs 0.000 description 5
235000019813 microcrystalline cellulose Nutrition 0.000 description 5
239000008108 microcrystalline cellulose Substances 0.000 description 5
210000002381 plasma Anatomy 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
238000004090 dissolution Methods 0.000 description 4
239000000725 suspension Substances 0.000 description 4
239000007888 film coating Substances 0.000 description 3
238000009501 film coating Methods 0.000 description 3
238000000227 grinding Methods 0.000 description 3
XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin hydrochloride Natural products CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 3
230000005855 radiation Effects 0.000 description 3
229960004586 rosiglitazone Drugs 0.000 description 3
238000012360 testing method Methods 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
229960004329 metformin hydrochloride Drugs 0.000 description 2
OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
239000008363 phosphate buffer Substances 0.000 description 2
HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
229960003271 rosiglitazone maleate Drugs 0.000 description 2
SUFUKZSWUHZXAV-BTJKTKAUSA-N rosiglitazone maleate Chemical compound [H+].[H+].[O-]C(=O)\C=C/C([O-])=O.C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O SUFUKZSWUHZXAV-BTJKTKAUSA-N 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
229940123208 Biguanide Drugs 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
208000013016 Hypoglycemia Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229920002774 Maltodextrin Polymers 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
229960002632 acarbose Drugs 0.000 description 1
XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
230000000181 anti-adherent effect Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
150000004283 biguanides Chemical class 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
238000005314 correlation function Methods 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000003316 glycosidase inhibitor Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
230000002218 hypoglycaemic effect Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229960001375 lactose Drugs 0.000 description 1
229960001021 lactose monohydrate Drugs 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
229960003105 metformin Drugs 0.000 description 1
229920001542 oligosaccharide Polymers 0.000 description 1
150000002482 oligosaccharides Chemical class 0.000 description 1
239000006187 pill Substances 0.000 description 1
229960005095 pioglitazone Drugs 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229940113115 polyethylene glycol 200 Drugs 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
229940068977 polysorbate 20 Drugs 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000004321 preservation Methods 0.000 description 1
239000008213 purified water Substances 0.000 description 1
229960002354 repaglinide Drugs 0.000 description 1
238000000790 scattering method Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000007873 sieving Methods 0.000 description 1
229940045902 sodium stearyl fumarate Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
230000009747 swallowing Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
239000000811 xylitol Substances 0.000 description 1
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
235000010447 xylitol Nutrition 0.000 description 1
229960002675 xylitol Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/52—Y being a hetero atom
- C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
- C07C311/57—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
- C07C311/59—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of rings other than six-membered aromatic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Diabetes (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Cephalosporin Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Plural Heterocyclic Compounds (AREA)

UA2002086718A 2000-01-14 2001-04-01 Glyburide in powdered form, tablets and capsules incorporating powdered glyburide, and metod for treating diabetes type ii UA73968C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US48370300A	2000-01-14	2000-01-14
PCT/US2001/000234 WO2001051463A1 (en)	2000-01-14	2001-01-04	Glyburide composition

Publications (1)

Publication Number	Publication Date
UA73968C2 true UA73968C2 (en)	2005-10-17

Family

ID=23921174

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2002086718A UA73968C2 (en)	2000-01-14	2001-04-01	Glyburide in powdered form, tablets and capsules incorporating powdered glyburide, and metod for treating diabetes type ii

Country Status (37)

Country	Link
US (2)	US20010036479A1 (et)
EP (1)	EP1250321B1 (et)
JP (1)	JP4787446B2 (et)
KR (1)	KR100739906B1 (et)
CN (1)	CN1210258C (et)
AR (1)	AR031547A1 (et)
AT (1)	ATE330937T1 (et)
AU (1)	AU771705B2 (et)
BG (1)	BG65782B1 (et)
BR (1)	BR0107564A (et)
CA (1)	CA2397294C (et)
CY (1)	CY1106328T1 (et)
CZ (1)	CZ20022429A3 (et)
DE (1)	DE60120916T2 (et)
DK (1)	DK1250321T3 (et)
EE (1)	EE05020B1 (et)
ES (1)	ES2264967T3 (et)
GE (1)	GEP20043299B (et)
HU (1)	HU228825B1 (et)
IL (2)	IL150383A0 (et)
LT (1)	LT5024B (et)
LV (1)	LV12914B (et)
MX (1)	MXPA02006835A (et)
MY (1)	MY128577A (et)
NO (1)	NO328152B1 (et)
NZ (1)	NZ519920A (et)
PT (1)	PT1250321E (et)
RO (1)	RO121381B1 (et)
RU (1)	RU2244707C2 (et)
SK (1)	SK286925B6 (et)
TN (1)	TNSN01005A1 (et)
TR (1)	TR200201798T2 (et)
TW (1)	TWI287989B (et)
UA (1)	UA73968C2 (et)
UY (1)	UY26529A1 (et)
WO (1)	WO2001051463A1 (et)
ZA (1)	ZA200205528B (et)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7767249B2 (en) *	2001-06-07	2010-08-03	Hewlett-Packard Development Company, L.P.	Preparation of nanoparticles
US20050271737A1 (en) *	2001-06-07	2005-12-08	Chinea Vanessa I	Application of a bioactive agent to a substrate
JP2005527537A (ja) *	2002-03-21	2005-09-15	テバファーマシューティカルインダストリーズリミティド	微小粒度ピオグリタゾン
EP1515701B1 (en)	2002-06-17	2014-09-17	Inventia Healthcare Private Limited	Process for the manufacture of multilayer tablet compositions comprising thiazolidinedione and biguanide
GEP20084570B (en)	2003-10-31	2008-12-25	Takeda Pharmaceutical	Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester
CN100455279C (zh) *	2004-04-29	2009-01-28	美时化学制药股份有限公司	口服延迟释放锭剂组成物及其制法
AU2004318976B2 (en) *	2004-04-29	2009-04-09	Lotus Pharmaceutical Co., Ltd.	Oral modified-release lozenges and their preparation method
CN100341495C (zh) *	2004-12-29	2007-10-10	三九医药股份有限公司	格列本脲固体分散体、口服组合物及其制备方法
WO2006109175A2 (en) *	2005-04-11	2006-10-19	Aurobindo Pharma Limited	Solid dosage form of an antidiabetic drug
US8529537B2 (en) *	2005-08-05	2013-09-10	Kimberly-Clark Worldwide, Inc.	Absorbent article with enclosures
ATE533488T1 (de)	2005-08-22	2011-12-15	Melior Pharmaceuticals I Inc	Verfahren und formulierungen zur modulierung von lyn-kinaseaktivität und behandlung assoziierter erkrankungen
CN101287467B (zh) *	2005-08-22	2011-01-19	梅里奥尔医药I公司	用于调节Lyn激酶活性和治疗相关病症的方法和制剂
US20090252790A1 (en) *	2006-05-13	2009-10-08	Novo Nordisk A/S	Tablet formulation
WO2008026668A1 (fr) *	2006-08-31	2008-03-06	Daiichi Sankyo Company, Limited	Composition médicale contenant un agent d'amélioration de la résistance à l'insuline
EP1967182A1 (en) *	2007-03-07	2008-09-10	KRKA, tovarna zdravil, d.d., Novo mesto	Pharmaceutical composition comprising a salt of rosigliatazone
US8552184B2 (en)	2008-07-03	2013-10-08	Melior Pharmaceuticals I, Inc.	Compounds and methods for treating disorders related to glucose metabolism
US8883852B2 (en)	2008-10-22	2014-11-11	University of Pittburgh—Of the Commonwealth System of Higher Education	Radioprotective agents
ES2982194T3 (es)	2009-02-13	2024-10-15	Boehringer Ingelheim Int	Composición farmacéutica que comprende derivados de glucopiranosilo, difenilmetano, forma de dosificación farmacéutica de la misma, proceso para su preparación y usos de la misma para el control glucémico mejorado en un paciente
US20130158055A1 (en)	2010-05-28	2013-06-20	Andrew G. Reaume	Prevention Of Pancreatic Beta Cell Degeneration
EP2520298A1 (en)	2011-05-03	2012-11-07	Assistance Publique, Hopitaux De Paris	Pharmaceutical composition comprising sulfonylureas (glibenclamide) or meglitinides for use for treating hyperglycaemia or for promoting growth of a premature infant
CN102743354A (zh) *	2012-07-31	2012-10-24	南京正科制药有限公司	瑞格列奈片及其制备方法
CN103142521B (zh) *	2013-03-21	2014-06-25	西南药业股份有限公司	格列本脲片及其制备方法
CN104127423A (zh) *	2014-07-30	2014-11-05	沈阳药科大学	格列喹酮衍生物及其制备方法和应用
CN104127424A (zh) *	2014-07-30	2014-11-05	沈阳药科大学	格列本脲衍生物及其制备方法和应用
AU2018250795B2 (en)	2017-04-10	2022-02-10	Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College	Treatment of adipocytes
CN113143940A (zh) *	2020-12-30	2021-07-23	成都恒瑞制药有限公司	一种抗糖尿病药物组合物的制备方法
WO2023012610A1 (en) *	2021-08-03	2023-02-09	Avaca Pharma Private Limited	Formulations, compositions and methods for the treatment of stroke

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3174901A (en) *	1963-01-31	1965-03-23	Jan Marcel Didier Aron Samuel	Process for the oral treatment of diabetes
DE1185180B (de)	1963-10-19	1965-01-14	Hoechst Ag	Verfahren zur Herstellung von Benzolsulfonylharnstoffen
US3454635A (en)	1965-07-27	1969-07-08	Hoechst Ag	Benzenesulfonyl-ureas and process for their manufacture
CA889876A (en)	1970-09-10	1972-01-04	Frank W. Horner Limited	Purification of glyburide
DE2348334C2 (de) *	1973-09-26	1982-11-11	Boehringer Mannheim Gmbh, 6800 Mannheim	Neue Zubereitungsform des N-4-[2-(5-Chlor-2-methoxybenzamido)äthyl]- phenyl-sulfonyl-N'-cyclohexylharnstoffs
US4060634A (en) *	1973-09-26	1977-11-29	Boehringer Mannheim G.M.B.H.	Rapidly resorbable glibenclamide
US4916163A (en) *	1985-06-04	1990-04-10	The Upjohn Company	Spray-dried lactose formulation of micronized glyburide
DE3833439A1 (de)	1988-10-01	1991-09-12	Hoechst Ag	Verfahren zur mikronisierung von glibenclamid
RU2026670C1 (ru)	1988-10-05	1995-01-20	Дзе Апджон Компани	Способ получения тонкодисперсного твердого фармацевтического вещества
US5258185A (en)	1989-08-23	1993-11-02	Bauer Kurt H	Highly active, rapidly absorbable formulations of glibenclamide, processes for the production thereof and their use
DE59206324D1 (de) *	1991-12-05	1996-06-20	Alfatec Pharma Gmbh	Pharmazeutisch applizierbares nanosol und verfahren zu seiner herstellung
DK36392D0 (da) *	1992-03-19	1992-03-19	Novo Nordisk As	Anvendelse af kemisk forbindelse
DE4323636A1 (de) *	1993-07-15	1995-01-19	Hoechst Ag	Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung
TWI238064B (en) *	1995-06-20	2005-08-21	Takeda Chemical Industries Ltd	A pharmaceutical composition for prophylaxis and treatment of diabetes
IT1276130B1 (it) *	1995-11-14	1997-10-27	Gentili Ist Spa	Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
US6153632A (en) *	1997-02-24	2000-11-28	Rieveley; Robert B.	Method and composition for the treatment of diabetes
DE19721467A1 (de) *	1997-05-22	1998-11-26	Basf Ag	Verfahren zur Herstellung kleinteiliger Zubereitungen biologisch aktiver Stoffe
CN1230171C (zh)	1997-06-18	2005-12-07	史密丝克莱恩比彻姆有限公司	用噻唑烷二酮和二甲双胍治疗糖尿病
GB9715306D0 (en)	1997-07-18	1997-09-24	Smithkline Beecham Plc	Novel method of treatment
PT996429E (pt) *	1997-10-27	2003-06-30	Merck Patent Gmbh	Solucoes e dispersoes no estado solido de farmacosfracamente soluveis em agua
SI0974356T1 (en)	1998-07-15	2003-12-31	Merck Sante	Tablets comprising a combination of metformin and glibenclamide
US6294192B1 (en) *	1999-02-26	2001-09-25	Lipocine, Inc.	Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US7374779B2 (en) *	1999-02-26	2008-05-20	Lipocine, Inc.	Pharmaceutical formulations and systems for improved absorption and multistage release of active agents

2000
- 2000-12-11 US US09/735,334 patent/US20010036479A1/en not_active Abandoned
- 2000-12-20 MY MYPI20005969A patent/MY128577A/en unknown
2001
- 2001-01-04 RO ROA200200979A patent/RO121381B1/ro unknown
- 2001-01-04 WO PCT/US2001/000234 patent/WO2001051463A1/en active IP Right Grant
- 2001-01-04 CA CA2397294A patent/CA2397294C/en not_active Expired - Lifetime
- 2001-01-04 IL IL15038301A patent/IL150383A0/xx active IP Right Grant
- 2001-01-04 CZ CZ20022429A patent/CZ20022429A3/cs unknown
- 2001-01-04 PT PT01900328T patent/PT1250321E/pt unknown
- 2001-01-04 GE GE4874A patent/GEP20043299B/en unknown
- 2001-01-04 DE DE60120916T patent/DE60120916T2/de not_active Expired - Lifetime
- 2001-01-04 NZ NZ519920A patent/NZ519920A/en not_active IP Right Cessation
- 2001-01-04 ES ES01900328T patent/ES2264967T3/es not_active Expired - Lifetime
- 2001-01-04 TR TR2002/01798T patent/TR200201798T2/xx unknown
- 2001-01-04 MX MXPA02006835A patent/MXPA02006835A/es active IP Right Grant
- 2001-01-04 RU RU2002121626/04A patent/RU2244707C2/ru active
- 2001-01-04 AU AU24740/01A patent/AU771705B2/en not_active Expired
- 2001-01-04 JP JP2001551845A patent/JP4787446B2/ja not_active Expired - Lifetime
- 2001-01-04 AT AT01900328T patent/ATE330937T1/de active
- 2001-01-04 EE EEP200200393A patent/EE05020B1/et unknown
- 2001-01-04 SK SK983-2002A patent/SK286925B6/sk not_active IP Right Cessation
- 2001-01-04 DK DK01900328T patent/DK1250321T3/da active
- 2001-01-04 CN CNB018036392A patent/CN1210258C/zh not_active Expired - Lifetime
- 2001-01-04 KR KR1020027009084A patent/KR100739906B1/ko active IP Right Grant
- 2001-01-04 EP EP01900328A patent/EP1250321B1/en not_active Expired - Lifetime
- 2001-01-04 HU HU0203852A patent/HU228825B1/hu unknown
- 2001-01-04 BR BR0107564-0A patent/BR0107564A/pt not_active Application Discontinuation
- 2001-01-08 TW TW090100369A patent/TWI287989B/zh not_active IP Right Cessation
- 2001-01-11 TN TNTNSN01005A patent/TNSN01005A1/en unknown
- 2001-01-11 UY UY26529A patent/UY26529A1/es not_active Application Discontinuation
- 2001-01-12 AR ARP010100161A patent/AR031547A1/es not_active Application Discontinuation
- 2001-04-01 UA UA2002086718A patent/UA73968C2/uk unknown
2002
- 2002-06-24 BG BG106870A patent/BG65782B1/bg unknown
- 2002-06-24 IL IL150383A patent/IL150383A/en unknown
- 2002-07-10 ZA ZA200205528A patent/ZA200205528B/xx unknown
- 2002-07-12 NO NO20023367A patent/NO328152B1/no not_active IP Right Cessation
- 2002-07-23 LT LT2002085A patent/LT5024B/lt not_active IP Right Cessation
- 2002-08-09 LV LVP-02-144A patent/LV12914B/en unknown
2003
- 2003-04-30 US US10/426,211 patent/US6830760B2/en not_active Expired - Lifetime
2006
- 2006-09-20 CY CY20061101349T patent/CY1106328T1/el unknown

Also Published As

Publication number	Publication date
BR0107564A (pt)	2002-10-01
HU228825B1 (en)	2013-05-28
IL150383A (en)	2007-03-08
DK1250321T3 (da)	2006-07-31
DE60120916D1 (de)	2006-08-03
CA2397294C (en)	2011-03-22
PL356210A1 (en)	2004-06-14
RU2244707C2 (ru)	2005-01-20
NO328152B1 (no)	2009-12-21
ATE330937T1 (de)	2006-07-15
LT2002085A (en)	2003-01-27
EE05020B1 (et)	2008-06-16
EP1250321A1 (en)	2002-10-23
IL150383A0 (en)	2002-12-01
LV12914B (en)	2003-01-20
AR031547A1 (es)	2003-09-24
US20010036479A1 (en)	2001-11-01
GEP20043299B (en)	2004-03-10
RU2002121626A (ru)	2004-01-10
CN1395560A (zh)	2003-02-05
NO20023367L (no)	2002-09-04
PT1250321E (pt)	2006-09-29
LT5024B (lt)	2003-06-25
ES2264967T3 (es)	2007-02-01
HUP0203852A2 (hu)	2003-04-28
DE60120916T2 (de)	2007-02-15
RO121381B1 (ro)	2007-04-30
HUP0203852A3 (en)	2005-05-30
NZ519920A (en)	2004-06-25
US6830760B2 (en)	2004-12-14
JP4787446B2 (ja)	2011-10-05
AU771705B2 (en)	2004-04-01
CN1210258C (zh)	2005-07-13
AU2474001A (en)	2001-07-24
MY128577A (en)	2007-02-28
ZA200205528B (en)	2003-10-10
TWI287989B (en)	2007-10-11
JP2003519681A (ja)	2003-06-24
WO2001051463A1 (en)	2001-07-19
MXPA02006835A (es)	2003-01-28
TR200201798T2 (tr)	2002-11-21
CA2397294A1 (en)	2001-07-19
EP1250321B1 (en)	2006-06-21
UY26529A1 (es)	2001-08-27
KR20020073169A (ko)	2002-09-19
SK9832002A3 (en)	2003-07-01
BG65782B1 (bg)	2009-11-30
TNSN01005A1 (en)	2005-11-10
US20030185880A1 (en)	2003-10-02
EE200200393A (et)	2003-10-15
KR100739906B1 (ko)	2007-07-16
CY1106328T1 (el)	2011-10-12
BG106870A (en)	2003-03-31
NO20023367D0 (no)	2002-07-12
SK286925B6 (sk)	2009-07-06
CZ20022429A3 (cs)	2003-06-18

Publication	Publication Date	Title
UA73968C2 (en)	2005-10-17	Glyburide in powdered form, tablets and capsules incorporating powdered glyburide, and metod for treating diabetes type ii
RU2226396C2 (ru)	2004-04-10	Твердая дозированная лекарственная форма для орального применения, содержащая комбинацию метформина и глибенкламида
RU2273472C2 (ru)	2006-04-10	Лекарственный состав, быстро распадающийся в ротовой полости, и способ его изготовления
WO2006109175A2 (en)	2006-10-19	Solid dosage form of an antidiabetic drug
Jeong et al.	2005	Frosta®: a new technology for making fast-melting tablets
US8367105B2 (en)	2013-02-05	Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
CA2264105C (en)	2007-04-24	Granulates comprising a water soluble compound and cellulose
CN105407876B (zh)	2019-08-30	抗结核病的稳定的包含异烟肼颗粒和利福喷汀颗粒的可分散的片剂及其制备方法
EP1729735B1 (en)	2007-06-27	Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
KR20040091135A (ko)	2004-10-27	염산 필지카이니드 함유 정제(건식)
KR20050002856A (ko)	2005-01-10	염산 필지카이니드 함유 정제(습식)
JPH11269067A (ja)	1999-10-05	ビタミンｅとｃを含有する速崩壊性錠剤
EP1787642A1 (en)	2007-05-23	Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby